y to Evaluate the E
fficacy, Safety, and Tolerability of A
ation in Subjects with Systemic L
upus Erythematosus), is designed to demonstrate that inhibition of both membrane bound and soluble BAFF with A-623 will improve patient clinical outcomes as measured by a composite SLE responder index. Lupus patients suffer from an inappropriate, chronic autoimmune response which often leads to severe skin rash, fatigue, joint pain, organ complications and cardiovascular disease.
About B-Cell Activating Factor (BAFF) and A-623
BAFF has been associated with a wide range of B-Cell mediated autoimmune diseases, including systemic lupus erythematosus, lupus nephritis, rheumatoid arthritis, multiple sclerosis, Sjogren's Syndrome, Graves' Disease and others. Multiple clinical studies with other BAFF antagonists recently have reported on BAFF's potential positive role in treating lupus and rheumatoid arthritis. Anthera is advancing its development of A-623, a broad inhibitor of BAFF, to expand its potential clinical utility in autoimmune diseases. A-623 is a novel fusion protein called a peptibody and is distinct from an antibody. Anthera owns worldwide rights to A-623 in all potential indications.
About Merck BioManufacturing Network
Merck BioManufacturing Network (known outside the USA and Canada as MSD BioManufacturing Network) is a full service CMO providing development and manufacturing services for biologics to pharmaceutical and biotechnology companies. It comprises the operations at Billingham, UK (formerly Avecia Biologics), and at Research Triangle Park, NC, USA (formerly Diosynth Biotechnology). Merck is known as MSD outside USA and Canada. For additional information about Merck BioManufacturing Network, please visit www.biomanufacturingnetwork.com.
About Anthera Pharmaceuticals
Anthera Pharmaceuticals is a biopharmaceutical company foc
Page: 1 2 3 4 Related medicine technology :1
|SOURCE Anthera Pharmaceuticals, Inc.|
Copyright©2010 PR Newswire.
All rights reserved
. Anthera Announces Update Call Regarding Vial Problems2
. Anthera Pharmaceuticals Reports 2010 Third Quarter Financial Results and Operational Update3
. Anthera Announces Third Quarter 2010 Financial Report and Conference Call4
. Anthera Pharmaceuticals Announces Pricing of $31.5 Million PIPE Financing5
. Anthera Pharmaceuticals to Present at Deutsche Bank Securities 35th Annual Health Care Conference6
. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors7
. Antheras Varespladib Meets Primary Endpoint in Phase 2 FRANCIS Trial for the Treatment of Acute Coronary Syndrome8
. Following Encouraging Results Anthera to Continue IMPACTS Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease9
. Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval10
. Anthera Pharmaceuticals Advances Global Development Strategy for Varespladib in Patients With Acute Coronary Syndrome With the Initiation of FRANCIS Trial11
. DSMB Supports Continuation of Anthera Phase II Impacts Trial for the Prevention of Acute Chest Syndrome in Patients With Sickle Cell Disease